SurvivorNet’s 2022 Close the Gap conference brought several important issues to light about the serious racial disparities that unfortunately exist when it comes to cancer prevention, detection and treatment.
These disparities were directly addressed during an enlightening panel with key industry leaders. Dr. Tania Small, Vice President, Global Medical Oncology Head, and Head of R&D Inclusion Diversity Council at GSK, led an important conversation.Read More
More so than anything, panelists agreed that a central focus on closing the gap when it comes to cancer should be about accessibility. NYU Langone’s Dr. Elaine Shum says that, “I think a lot of it does begin with access to clinical trials and education about the trials… I think industry is one area that definitely can help us in terms of increasing the awareness about trials to encourage more enrollment, because it is so important that we get a bigger picture of how a drug might work in not just a white population.”
Karima Sharif, who heads inclusive investments and partnerships at Publicis Health Media, echoed doctors’ messages on awareness, but from an marketing standpoint: “From a media perspective, we’re thinking about the distribution. If we know that we want to activate within the communities, then we’re working with our clients.”
Above all, the industry panel agreed that the main focus is access and practical thinking. Making things more accessible and considering a wider scope of patients in trials. access and awareness is immediately limited when groups of people are excluded from test runs.
Watch the full conference here.
Learn more about SurvivorNet's rigorous medical review process.